Recovering scientist turned early stage VC A biotech optimist fighting gravity

Biotech Analyst Optimism: Price Targets Post-IPO
August 29, 2014

Getting high quality analyst coverage of your company as a recently minted IPO is important for communicating the rationale and excitement around your story. Thoughtful analysts can evangelize (or punish) companies they believe in (or not). But understanding the relationship

7 Comments

Advancing A New Drug Modality: A Few Lessons Learned
August 21, 2014

Translating breakthrough science into breakthrough medicines is a daunting task.  It’s also worth every nail-biting minute waiting for the next result that brings you closer to helping a patient in need.  We started miRagen based on some amazing laboratory results

Leave a comment

Target Practice
August 18, 2014

Every life sciences company needs to make good program choices.  Big pharma creates value through smart portfolio management while small biotech companies can be defined by a single lead asset.  In both cases, the opportunity cost of poor decision-making can

Leave a comment

Data Insight: The Return Distribution Of BioPharma VC Financings
August 11, 2014

Return distributions in venture capital across different sectors have been a frequent source of commentary, and new data from Correlation Ventures provides further substrate for that theme. I’ve highlighted data from Correlation Ventures (CV) in the past, looking at top

1 Comment

VC-Backed Biotech IPOs: Valuations And Virtuous Cycles
August 4, 2014

As everyone in biotech knows, the last eighteen months have been an unprecedented time in the public capital markets.   2014 is on track to become the best year ever for life science IPOs, topping both 2013 and 2000.  Last week

Leave a comment

Lessons From An IPO
July 22, 2014

Raising money is a huge part of being a CEO, but nothing can fully prepare you for the experience of taking your company public.   Together with our team at Zafgen, I recently had the experience of taking our company public

4 Comments

Framing Up Capital Efficiency In Early Stage Biotech
July 17, 2014

Capital efficiency has become a mantra at Atlas, one shared by a number of other early stage biotech investors. It’s a term often repeated in discussions about building young companies, and yet it has become clear that there’s no consistent

4 Comments

Patients: Our Purpose, Our Partners
July 9, 2014

My first experience in this life sciences industry, many years ago, was working as a pharmacist in a small town in the midwest. My most valued memories from that time were the instances when I was able to engage directly

2 Comments

Growing Beyond The Startup Phase: Lessons learned
July 1, 2014

So your biotech startup’s graduated to a Series A financing and your investors believe there’s nothing but champagne and robust clinical data in your future. Some classic analogies are applicable here; you’ve found a way off the island, you’ve defeated

Leave a comment

Soccer, The World Cup, And Biotech
June 30, 2014

Soccer is a fantastic sport – eleven players on a side, a hundred yards of pitch, one ball, and lots of emotion. Watching the World Cup this year has been fun; our children are just now old enough where they

5 Comments

Operating Inside The Atlas Seed Portfolio
June 27, 2014

In early 2013, I enlisted as an entrepreneur-in-residence (EIR) with the Atlas Venture life science investment team as the firm focused on a seed-led investing strategy as a core tenant of Fund IX (here).  I viewed it as a great

1 Comment

Zafgen Supersizes Its Obesity-Focused IPO: An Early Investor’s Reflections
June 25, 2014

Last week we priced the IPO for Zafgen – embarking on a new phase for the company (here).  Upsized at the top of the range, the offering is a testimony to the great team and exciting story at Zafgen. In line

1 Comment